Loading
A phase 2 trial of Pembrolizumab, Cyclophosphamide in diffuse large b-cell lymphoma, run by ImmunoVaccine Technologies, Inc. (IMV Inc.), now recruiting.
DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma is a phase 2 interventional study registered as NCT04920617 by ImmunoVaccine Technologies, Inc. (IMV Inc.), with 102 participants planned, started 2021-06-18 and due to reach its primary completion in 2024-10. Interventions recorded: DPX-Survivac, Pembrolizumab, CPA. Conditions listed: Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/